Omeros Corp
OMER6.590USD
+0.010+0.15%
收盤 11/07, 16:00（美東）報價延遲15分鐘
395.55M總市值
虧損本益比TTM
關於 Omeros Corp 公司
Omeros Corporation 是一家生物製藥公司。該公司專注於發現、開發和商業化小分子和蛋白質療法，用於治療免疫疾病（包括補體介導的疾病、癌症以及成癮和強迫症）的大市場和孤兒適應症。其主要 MASP-2 抑制劑 narsoplimab 靶向補體的凝集素途徑，是 FDA 正在等待批准的生物製劑許可申請的主題，用於治療造血幹細胞移植相關的血栓性微血管病。其長效 MASP-2 抑制劑 OMS1029 正處於 I 期多劑量遞增臨牀試驗中。其 MASP-3 抑制劑 OMS906 是補體替代途徑的關鍵激活劑，正在陣發性睡眠性血紅蛋白尿和補體 3 腎小球病的臨牀項目中取得進展。該公司的主要磷酸二酯酶 7 抑制劑 OMS527 目前正在進行治療可卡因使用障礙的臨牀開發。
Omeros Corp簡介
公司代碼OMER
公司名稱Omeros Corp
上市日期Oct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
員工數量202
證券類型Ordinary Share
年結日Oct 08
公司地址201 Elliott Avenue West
城市SEATTLE
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編98119
電話12066765000
網址https://www.omeros.com/
公司代碼OMER
上市日期Oct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
Omeros Corp公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Dr. Thomas F. Bumol, Ph.D.
Dr. Thomas F. Bumol, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine A. Melfi, Ph.D.
Dr. Catherine A. Melfi, Ph.D.
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
--
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. David J. Borges
Mr. David J. Borges
Chief Accounting Officer, Vice President - Finance, Treasurer
Chief Accounting Officer, Vice President - Finance, Treasurer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 11月8日 週六
更新時間: 11月8日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Ingalls & Snyder LLC (Asset Management)
6.03%
BlackRock Institutional Trust Company, N.A.
5.43%
The Vanguard Group, Inc.
4.92%
D. E. Shaw & Co., L.P.
2.42%
Stifel, Nicolaus & Company, Incorporated
2.24%
其他
78.96%
持股股東
持股股東
佔比
Ingalls & Snyder LLC (Asset Management)
6.03%
BlackRock Institutional Trust Company, N.A.
5.43%
The Vanguard Group, Inc.
4.92%
D. E. Shaw & Co., L.P.
2.42%
Stifel, Nicolaus & Company, Incorporated
2.24%
其他
78.96%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
16.48%
Investment Advisor
15.58%
Hedge Fund
6.07%
Research Firm
3.82%
Individual Investor
2.90%
Bank and Trust
0.88%
Insurance Company
0.12%
Venture Capital
0.09%
Pension Fund
0.05%
其他
53.99%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
243
29.83M
43.83%
+1.23M
2025Q2
255
30.16M
44.94%
-422.08K
2025Q1
263
30.38M
51.89%
-522.27K
2024Q4
256
29.32M
50.59%
-441.66K
2024Q3
242
27.89M
48.13%
-1.92M
2024Q2
248
27.65M
47.72%
-3.10M
2024Q1
269
28.11M
48.16%
-3.03M
2023Q4
275
27.52M
43.79%
-6.21M
2023Q3
299
30.25M
48.14%
-4.77M
2023Q2
303
29.52M
46.99%
+306.67K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Ingalls & Snyder LLC (Asset Management)
3.98M
5.85%
+5.10K
+0.13%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.69M
5.43%
-328.94K
-8.18%
Jun 30, 2025
The Vanguard Group, Inc.
3.28M
4.82%
+46.32K
+1.43%
Jun 30, 2025
D. E. Shaw & Co., L.P.
1.65M
2.42%
-291.10K
-15.02%
Jun 30, 2025
Stifel, Nicolaus & Company, Incorporated
1.52M
2.24%
-33.76K
-2.17%
Jun 30, 2025
Demopulos (Gregory A. M.D.)
2.03M
2.98%
--
--
May 23, 2025
Geode Capital Management, L.L.C.
1.37M
2.01%
+739.00
+0.05%
Jun 30, 2025
State Street Investment Management (US)
1.20M
1.76%
-156.01K
-11.50%
Jun 30, 2025
Two Sigma Investments, LP
1.09M
1.61%
+971.88K
+802.28%
Jun 30, 2025
Morgan Stanley & Co. LLC
1.09M
1.6%
+501.25K
+85.73%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.48%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比0.48%
iShares Micro-Cap ETF
佔比0.05%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
ProShares UltraPro Russell2000
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
iShares Russell 2000 Growth ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
